Liposomal adjuvants for human vaccines

@article{Alving2016LiposomalAF,
  title={Liposomal adjuvants for human vaccines},
  author={Carl R. Alving and Zoltan Beck and Gary R. Matyas and Mangala Rao},
  journal={Expert Opinion on Drug Delivery},
  year={2016},
  volume={13},
  pages={807 - 816}
}
  • C. Alving, Z. Beck, M. Rao
  • Published 25 February 2016
  • Biology, Chemistry
  • Expert Opinion on Drug Delivery
ABSTRACT Introduction: Liposomes are well-known as drug carriers, and are now critical components of two of six types of adjuvants present in licensed vaccines. The liposomal vaccine adjuvant field has long been dynamic and innovative, and research in this area is further examined as new commercial products appear in parallel with new vaccines. In an arena where successful products exist the potential for new types of vaccines with liposomal adjuvants, and alternative liposomal adjuvants that… 
Liposome Formulations as Adjuvants for Vaccines.
TLDR
The Army Liposome Formulation (ALF) family of vaccine adjuvants, which have been developed and improved since 1986, and which range from nanosize to microsize, are currently being employed in phase 1 studies with different types of candidate vaccines.
Liposomes as Adjuvants and Vaccine Delivery Systems
TLDR
The review briefly describes some of the fundamental mechanisms underlying the mobilization of immunity when encountering an antigen, as well as the influence of liposome carriers on the processes of internalization of antigens by immunocompetent cells and ways of immune response induction.
Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines.
TLDR
Cationic liposomes can provide long-term storage of subunit TB vaccines at the injection site, confer strong electrostatic interactions with APCs, potentiate both humoral and cellular immune responses, and induce a strong memory response by the immune system, which suggest the use of cationicliposomes to produce an efficient vaccine against TB infections.
Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization
An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery
TLDR
N nanoscale-based adjuvants and delivery vehicles such as viral vectors, virus-like particles and virosomes; non-viral vectors namely nanoemulsions, lipid nanocarriers, biodegradable and non-degradable nanoparticles, calcium phosphate nanoparticles and colloidally stable nanoparticles; and pattern recognition receptors covering c-type lectin receptors and toll-like receptors are summarized.
Adjuvants for HIV vaccines
TLDR
Understanding the interplay of innate and adaptive immune responses that can be harnessed by adjuvant formulations would aid in the rational design of a well tolerated and effective vaccine formulation that can block HIV at the site of transmission.
Cationic lipids as one‐component vaccine adjuvants: A promising alternative to alum
Toward precision adjuvants: optimizing science and safety
TLDR
Adjuvants enhance vaccine immunogenicity and can be associated with reactogenicity, and novel multidisciplinary approaches hold promise to accelerate and de-risk targeted adjuvant discovery and development.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 111 REFERENCES
Liposomal vaccine delivery systems
TLDR
This paper reviews liposomal adjuvants now in vaccine development, with particular emphasis on their adjuvant mechanism and how specific physicochemical characteristics of liposomes affect the immune response.
Liposomes as vaccine delivery systems: a review of the recent advances
TLDR
This review concentrates on recent and relevant studies emphasizing current reports dealing with the most studied antigens and adjuvants, and pertinent examples of vaccines.
Influenza virosomes as an efficient system for adjuvanted vaccine delivery
TLDR
In humans, virosome-based vaccines containing inactivated hepatitis A and influenza antigens have been found to be efficacious and well-tolerated and have been on the market for several years.
Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.
  • L. Fries, D. Gordon, C. Alving
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1992
TLDR
It is concluded that encapsulation of poorly immunogenic circumsporozoite protein repeat peptides in monophosphoryl lipid A-containing liposomes is a successful adjuvant strategy in humans for inducing high levels of specific antibody production.
Liposomal presentation of antigens for human vaccines.
  • R. Glück
  • Biology, Chemistry
    Pharmaceutical biotechnology
  • 1995
TLDR
Analysis of the various techniques used to ensure the efficacy, stability, homogeneity, and safety of liposomal vaccine have been discussed.
Liposomal Vaccines: Clinical Status and Immunological Presentation for Humoral and Cellular Immunity
  • C. Alving
  • Biology, Medicine
    Annals of the New York Academy of Sciences
  • 1995
TLDR
The intracellular cytoplasmic trafficking patterns of liposomal antigens raise the possibility that liposomes may have utility in human vaccines for induction of either humoral immunity or cytotoxic T lymphocytes.
...
1
2
3
4
5
...